View Clinical Trial (Medical Research Study)
Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia
| City: |
|
Hamilton |
| State: |
|
New Jersey |
| Zip Code: |
|
08619 |
| Conditions: |
|
Attention-Deficit/Hyperactivity Disorder - Attention Deficit Disorder - Insomnia - Sleep Disorders |
| Purpose: |
|
This study seeks to determine, using special sleep tests (polysomnography and actigraphy) if
guanfacine extended release is able to improve nighttime sleep in children with ADHD -
associated insomnia while improving daytime ADHD symptoms. Male and female children with
diagnosed or suspected ADHD with sleep problems (difficulty falling asleep, difficulty
staying asleep, or less than expected hours of sleep) will be recruited. After obtaining
informed consent and assent (when appropriate) and after discontinuation of excluded
medications, children will have evaluations of his or her sleep and evaluations confirming
the ADHD diagnosis. Children who successfully pass screening will be enrolled into the
double-blind, placebo-controlled, randomized investigation with 50% of participants
receiving guanfacine extended release and 50% of participants receiving matching placebo.
Using a flexible-dose optimization design based on ADHD symptom improvement and medication
tolerability, the dose will be adjusted between 1 to 4 mg over the course of four weeks. At
the end of medication adjustment (week 4 or 5), ADHD questionnaires, sleep questionnaires,
and sleep tests will be repeated and analyzed. The medication will be weaned over the course
of the following 3-10 days.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
1. Subject must be male or female, aged 6 - 12 years with ADHD.
2. Subject must (a) be taking methylphenidate, amphetamine, or atomoxetine for treatment
of ADHD with parent or subject concerns of inadequate efficacy or intolerable side
effects, or (b) free of any other medication used to treat ADHD for at least 30 days
at the time of the initial sleep study.
3. Subject must have repeated difficulty with sleep initiation or persistence despite
attempts at adequate sleep hygiene.
4. Subject must be able to swallow tablets.
Exclusion Criteria:
1. Subject or parent/LAR is unable or unwilling to discontinue present medications used
to treat ADHD.
2. Subject has a body mass index < 5th percentile for age, using the Centers for Disease
Control standards reported in 2000.
3. Subject has a body weight > 176 pounds.
4. Subject has a diagnosis of Autism or Autism Spectrum Disorder.
5. Subject has other serious psychiatric diagnoses.
6. Subject has a medical condition that may require treatment with an unapproved
medication, that may cause a safety concern, or that may confound outcome results
7. Subject has an excessive caffeine intake (greater than 2.5 mg/kg/d).
8. Subject has a prior problem with clonidine or guanfacine.
|
| NCT ID: |
|
NCT01156051 |
| Primary Contact: |
|
Principal Investigator
Thomas A Rugino, MD
Children's Specialized Hospital
Thomas A Rugino, MD
Phone: 888-244-5373 ext. 5705
Email: research@childrens-specialized.org
|
| Backup Contact: |
|
Email: research@childrens-specialized.org
Nicole Henken-Siefken, BS
Phone: 888-244-5373 ext. 3719
|
| Location Contact: |
|
Hamilton, New Jersey 08619
United States
Thomas A Rugino, MD
Phone: 888-244-5373
Email: research@childrens-specialized.org
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 22, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|